News
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they contract respiratory syncytial virus. Previously the vaccine, sold under the name mResvia, was only licensed for use in adults aged 60 and older.
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
New Scientist on MSN8d
Infant RSV shot may be more effective than vaccines during pregnancyWhen an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...
Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback